Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02391818 · ClinicalTrials.gov registry record
The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients
A clinical trial, sponsored by OSF Healthcare System.
- Completed
- Registry status
- 19
- Enrollment target
NCT02391818: Completed study, sponsored by OSF Healthcare System.
NCT02391818 is a clinical trial that has completed, run by OSF Healthcare System. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02391818 has completed, sponsored by OSF Healthcare System.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
The purpose of this study is to quantify the balance impairments during and after taxane chemotherapy. Disability due to balance impairments caused by chemotherapy induced peripheral neuropathy (CIPN) can cause falls, injury, and a decline in independence. This results in poor treatment outcomes such as greater morbidity and mortality, inability to complete treatment protocols, self-limitation of activity, and diminished quality of life.
Primary Outcome
assessment of static balance under conditions eyes open on firm surface, eyes closed on firm surface, eyes open on foam surface, and eyes closed on foam surface
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-02 |
| Est. Completion | 2017-06-16 |
What the finished NCT02391818 record still lists
NCT02391818 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02391818 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02391818 about?
NCT02391818 is a clinical study titled "The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients". The purpose of this study is to quantify the balance impairments during and after taxane chemotherapy. Disability due to balance impairments caused by chemotherapy induced peripheral neuropathy (CIPN) can cause falls, injury, and a decline in independence. This results in poor treatment outcomes suc...
What is the current status of trial NCT02391818?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2015-02. Estimated completion is 2017-06-16.
Who is sponsoring clinical trial NCT02391818?
This trial is sponsored by OSF Healthcare System, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia